The present invention relates to topical negative pressure (TNP) therapy particularly, though not exclusively, to the control of negative pressure within a wound dressing.
TNP therapy has assumed great importance in recent years due to the beneficial effects of TNP therapy on a healing wound and also because of the accelerated healing which TNP therapy provides.
Apparatus for TNP therapy ranges from extremely complex apparatus only really suitable for use in a specialised hospital environment to much smaller and simpler, portable apparatus which may be used by an individual patient at home or at work.
The basic principle of TNP therapy is to create a closed cavity over the wound itself by means of a thin, flexible sealing film adhered to the patient's sound skin surrounding the wound; admitting one end of an aspirant conduit into the closed cavity, the conduit being sealed to the flexible film, for example; and connecting a distal end of the aspirant conduit to a vacuum source such as an electrically driven vacuum pump, for example, to create a pressure lower than the surrounding ambient atmospheric pressure within the wound cavity. As is known to the skilled person the lower pressure creates many beneficial therapeutic effects on the wound including increased blood flow to the wound and faster granulation of tissue, for example.
As noted above TNP therapy may be applied by a diverse range of apparatus. However, in general terms the more complex apparatus tends to be used on larger, more serious wounds which require a more intensive and varied treatments by TNP therapy. Examples of apparatus useful in the context of treatment of such larger wounds are given below.
In our co-pending International patent application, WO 2004/037334, apparatus, a wound dressing and a method for aspirating, irrigating and cleansing wounds are described. In very general terms, this invention describes the treatment of a wound by the application of topical negative pressure (TNP) therapy for aspirating the wound together with the further provision of additional fluid for irrigating and/or cleansing the wound, which fluid, comprising both wound exudates and irrigation fluid, is then drawn off by the aspiration means and circulated through means for separating the beneficial materials therein from deleterious materials. The materials which are beneficial to wound healing are recirculated through the wound dressing and those materials deleterious to wound healing are discarded to a waste collection bag or vessel.
In our co-pending International patent application, WO 2005/04670, apparatus, a wound dressing and a method for cleansing a wound using aspiration, irrigation and cleansing wounds are described. Again, in very general terms, the invention described in this document utilises similar apparatus to that in WO 2004/037334 with regard to the aspiration, irrigation and cleansing of the wound, however, it further includes the important additional step of providing heating means to control the temperature of that beneficial material being returned to the wound site/dressing so that it is at an optimum temperature, for example, to have the most efficacious therapeutic effect on the wound.
In our co-pending International patent application, WO 2005/105180, apparatus and a method for the aspiration, irrigation and/or cleansing of wounds are described. Again, in very general terms, this document describes similar apparatus to the two previously mentioned documents hereinabove but with the additional step of providing means for the supply and application of physiologically active agents to the wound site/dressing to promote wound healing.
The content of the above references is included herein by reference.
However, the above apparatus and methods are generally only applicable to a patient when hospitalised as the apparatus is complex, needing people having specialist knowledge in how to operate and maintain the apparatus, and also relatively heavy and bulky, not being adapted for easy mobility outside of a hospital environment by a patient, for example.
Whilst the above examples are mainly relevant to the treatment of larger wounds, there is also a need for the treatment of relatively small wounds where the patient may otherwise be fit and mobile and require treatment outside of a clinical setting such as at home or at their workplace but where the provision of TNP therapy is desirable but nevertheless need to provide controlled conditions in the wound cavity. An example of a suitable apparatus is described in our co-pending UK patent application, GB0712736.8, of common ownership herewith, the content of which is included herein by reference.
An unexpected problem with smaller wounds of relatively low surface area is that they are relatively easy to seal in that they generally may have a relatively large area of sound flesh surrounding them and hence have large sealing borders therearound for the sealing film or drape to seal with and which tends to mitigate against inward air leaks from this area of the dressing. Secondly, even though the sealing films, which are well known to those skilled in the art, tend to be semi-permeable membrane type materials which allow to an extent the passage of gas such as air and water vapour, they do so only to a limited extent which is defined or measured in mass flow per unit area, Thus, since the area of the sealing film above the wound is relatively small, the amount of permitted gaseous flow is small. Because the seal over and around the wound may be very good, it is easy to create a vacuum in the wound cavity which does not decay quickly due to leaks, and therefore, very little or no flow through the aspirant conduit may result and whilst the vacuum is there over the wound, the wound exudate may not be being transported away to a waste canister, for example, and may be stagnating at the wound itself, this being especially so at low levels of negative pressure relative to atmospheric pressure. One important feature of TNP therapy is that the wound exudate fluid is desirably transported away from the wound site. Failure to achieve this efficiently may result in increased risk of infection and in the worst cases may result in back flow of wound exudate into the wound cavity.
However, whether the wound is large or small the fact is that clinicians strive to seal the wound as well as they possibly can so as to prevent bacteria from causing infection. Larger wounds generate greater volumes of fluid and, are therefore, susceptible to filling the wound cavity with fluid. Furthermore, it is possible for the aspiration conduit to fill with exudate fluid resulting in a pressure differential between the wound and the vacuum source due to the viscous drag of the exudate and the height differential between wound and vacuum source.
It is an object of the present invention to mitigate such problems especially, but not exclusively, in portable TNP therapy apparatus and to provide apparatus and a method where reliable flow of wound exudate away from the wound is promoted.
According to a first aspect of the present invention there is provided apparatus for the provision of TNP therapy to a wound, the apparatus comprising: a sealing membrane for covering a wound to form a wound cavity in use; an aspirant conduit having one end thereof operably associated with the wound cavity, in use; vacuum means provided at a distal end of the aspirant conduit for applying a vacuum to the wound cavity when in use; and, air bleed means in fluid communication with the wound cavity when in use.
In this specification the term “vacuum” means a pressure less than ambient atmospheric pressure.
The air bleed means may be switchable in that the air bleed may be turned on and off as desired. In this regard the air bleed means may be provided by a second conduit having one end in communication with the wound cavity and having a filter associated with the conduit and a clamp or valve which enables the filter to admit air from the surrounding atmosphere to the wound cavity under the influence of the vacuum in the wound cavity. Air flow into the conduit may be controlled by the clamp on the conduit or on/off valve controlled by the user/patient or a clinician. An air bleed may be admitted when, for example, the patient observes that the aspirant tube appears to be full of exudate but which is not moving. Opening of the conduit to ambient air then induces a fluid flow in the conduit to expel the exudate into a waste canister, for example, associated with particular TNP apparatus in use.
The air bleed means may provide a maximum flow rate at 200 mmHg below atmospheric of up to 1 l/min into the system. Preferably, the flow rate may be a maximum of 0.5 l/min. More preferably the flow rate may be a maximum of 0.2 l/min. More preferably still, a maximum flow rate of 0.05 l/min may be provided into the system. The overriding factor is to achieve a flow rate consistent with the wound not drying out as may happen if the incoming flow rate of bleed air is too high.
Control of bleed rate may be achieved by control of the area of the filter through which bleed air may be admitted.
Use of a filter is both desirable and advantageous in minimising the risk of pathogens from being admitted to the wound cavity by the air bleed.
The use of a regulator on the second conduit described above may also be employed to achieve a constant but controlled rate of inward air bleed.
Alternatively, the air bleed means may be associated with the sealing drape in which an aperture may be formed to permit the attachment of an air bleed port thereto. Such an air bleed port may have a filter portion or aperture through which ambient air is drawn into the wound cavity by the vacuum. Such an air bleed port may be permanently open to ambient atmosphere but, due to the contained filter portion, may restrict the rate of flow of air into the wound cavity or aspirant conduit to a low rate due to the size of the filter pores. In effect such an air bleed port substitutes for leakage of air into a TNP dressing which normally occurs with larger wounds. Suitable air bleed ports may be manufactured from soft plastics material mouldings so as not to cause trauma to a patient if lain upon. They may be provided during manufacture with a layer of adhesive thereon and suitable protective layer of siliconised paper until needed for use.
Such air bleed ports may be sealed off with suitable sealing tape so as to be able to check for leaks in the dressing and/or act as an on/off facility.
An air bleed provision may be provided by a second conduit plugged into a suitable grommet sandwiched between two adhesive drape or sealing membrane layers for example as described in our co-pending International patent application, PCT/US2007/074374, based on GB0712735.0, of common ownership herewith and the content of which are included herein by reference.
Suitable filters may be 0.2 or 0.1 or 0.02 micron filters, for example, which also have the added advantage in that they may also prevent expulsion of bacteria to atmosphere in the reverse direction if for any reason this might occur.
An advantage of the present invention is that use of a filter element of predetermined pore size and area permits close control of a desired low flow rate of ambient air into the wound cavity, the filter element itself also preventing ingress of potentially harmful bacteria. In contrast, conventional valves are insufficiently sensitive to control at the low flow rates required and also do not stop harmful bacterial from entering the wound.
In some embodiments of the present invention an air bleed port such as that described above may be provided with the drape or sealing membrane material during manufacture thereof, the air bleed port being adhered or welded to the drape or flexible sealing membrane.
In all embodiments of the present invention the rate of bleed air flow into the dressing and wound cavity is controlled solely by the characteristics of the filter with respect to its pore size and area exposed to ambient atmosphere.
According to a second aspect of the present invention there is provided an air bleed port member for use with a topical negative pressure dressing.
According to a third aspect of the present invention there is provided a method of providing topical negative pressure therapy to a wound, the method comprising the steps of: providing a sealing membrane for covering a wound to form a wound cavity; providing an aspirant conduit having one end thereof operably associated with the wound cavity; providing vacuum means provided at a distal end of the aspirant conduit for applying a vacuum to the wound cavity; and, air bleed means in fluid communication with the wound cavity.
In order that the present invention may be more fully understood, examples will now be described by way of illustration only with reference to the accompanying drawings, of which:
Referring now to the drawings and where the same features are designated by common reference numerals.
In operation the vacuum pump is turned on and a vacuum is created in the wound cavity 17. If the wound cavity is well sealed with no or very little leakage, wound exudate fluid may not be transported along the conduit portion 22 to a waste receptacle (not shown) associated with the vacuum pump 26 since there is little or no air/fluid flow along the conduit 22. In this event the pinch clamp 34 may be opened so that an air bleed is admitted through the filter element 42 into the wound cavity 17 thus stimulating a fluid flow through the wound cavity 17 and through the conduit 22 towards the pump 26 so keeping the conduit 22 unblocked and free flowing. The pinch clamp 34 has no effect on the flow rate of the air bleed, merely controlling whether there is or is not flow through the conduit 30, all flow control being decided by the pore size and area of the filter element 42.
In this instance the filter 42 is a 0.2 micron pore size, antimicrobial filter
The pinch clamp may be left open so that the conduit 30 is permanently open in the event that the wound cavity is particularly well sealed so providing a constant air bleed whilst the vacuum pump 26 is running.
To use the air bleed port member, a hole (not shown) is made in the membrane (not shown) covering the wound commensurate with the size of the aperture 304, the protective paper layer 318 us removed and the air bleed port 300 adhered to the upper surface of the sealing membrane with the hole in the membrane and the aperture 304 in communication with each other.
In a preferred construction the air bleed port 300 may be provided as part of a dressing membrane with the port 300 and membrane adhered or welded (in the latter case there is no adhesive layer 316) together during manufacture.
In operation the vacuum pump 524 generates a predetermined vacuum level in the cavity 534 which causes the membrane 504 to be pushed down onto the porous, resiliently compressible wound filling element 502 by the ambient excess air pressure and the apertures 508, 514 to come into direct contact with the top surface of the resiliently compressible foam material 502 thus aspirating wound exudate which permeates through the wound filling element 502 to the waste canister (not shown). Whilst the wound exudate is being aspirated, the air bleed hole 528 and filter 532 permit a continuous controlled rate air bleed into the conduit 522 preventing the aspiration of wound exudate from stagnating. If, for any reason, it is desired to stop the air bleed then this can be terminated by the simple expedient of placing a piece of non-porous adhesive tape over the hole and filter 532.
The port described with reference to
An important advantage of the port according to the embodiment of
This port also adheres to the sealing membrane surface or may be pre-prepared by adhering or welding the port thereto as a unit. Where the port member 600 has a layer of adhesive on the underside of flange portion 602 it may be provided with a protector layer of siliconised paper or PE film (not shown) to be removed by the user immediately before application to a flexible sealing membrane (not shown).
In use the port of
Although resiliently compressible wound filling elements have been described above it is only necessary for the wound filling element to remain porous when the maximum desired vacuum is applied and it is not necessary that it also be resiliently compressible. The air bleed port of
In operation the wound cavity is evacuated to a desired pressure via the conduit 714 whilst a small but continuous air bleed through the hole 710 and filter in the recess 712 prevents wound exudate from stagnating due to a no-flow condition in the aspirant conduit 714. The flexible bellows portion 708 maintains the conduit 714 spaced-apart from the air bleed hole 710 thus preventing the hole from becoming blocked by the conduit surface due to the vacuum in the wound cavity.
As with previous embodiments the port 700 may be provided as a unit with a flexible sealing membrane by being adhered or welded thereto.
A further embodiment of an air bleed port member is shown in
Air bleed ports may be sterile packaged having an air bleed rate and associated pressure or pressure range printed thereon.
The air bleed port member of
In the case of the port of
Throughout the description and claims of this specification, the words “comprise” and “contain” and variations of the words, for example “comprising” and “comprises”, means “including but not limited to”, and is not intended to (and does not) exclude other moieties, additives, components, integers or steps.
Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.
Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith.
Number | Date | Country | Kind |
---|---|---|---|
0723872.8 | Dec 2007 | GB | national |
The present application is a continuation of U.S. patent application Ser. No. 14/221,045, filed on Mar. 20, 2014, entitled “APPARATUS FOR TOPICAL NEGATIVE PRESSURE THERAPY,” which is a continuation of U.S. patent application Ser. No. 12/746,458, filed on Jun. 4, 2010, entitled “APPARATUS FOR TOPICAL NEGATIVE PRESSURE THERAPY,” which is a national phase application under 35 U.S.C. § 371 of International Application No. PCT/GB2008/051118, filed on Nov. 26, 2008, entitled “APPARATUS FOR TOPICAL NEGATIVE PRESSURE THERAPY,” which claims the benefit of Great Britain Application No. 0723872.8, filed Dec. 6, 2007, entitled “APPARATUS FOR TOPICAL NEGATIVE PRESSURE THERAPY,” the entire contents of each of which is hereby incorporated by reference herein in their entirety and for all purposes.
Number | Name | Date | Kind |
---|---|---|---|
3382867 | Reaves | May 1968 | A |
3568675 | Harvey | Mar 1971 | A |
3633567 | Sarnoff | Jan 1972 | A |
3902484 | Winters | Sep 1975 | A |
3943734 | Fleissner | Mar 1976 | A |
4135515 | Muriot | Jan 1979 | A |
4306558 | Kurtz et al. | Dec 1981 | A |
4605399 | Weston et al. | Aug 1986 | A |
4710165 | McNeil et al. | Dec 1987 | A |
4822743 | Wegrzyn | Apr 1989 | A |
4869271 | Idris | Sep 1989 | A |
4903710 | Jessamine | Feb 1990 | A |
4921492 | Schultz | May 1990 | A |
4969880 | Zamierowski | Nov 1990 | A |
5042981 | Gross | Aug 1991 | A |
5088483 | Heinecke | Feb 1992 | A |
5100396 | Zamierowski | Mar 1992 | A |
5106362 | Gilman | Apr 1992 | A |
5154712 | Herweck | Oct 1992 | A |
5160315 | Heinecke et al. | Nov 1992 | A |
5180375 | Feibus | Jan 1993 | A |
5183763 | Mallow | Feb 1993 | A |
5218212 | Sato | Jun 1993 | A |
5261893 | Zamierowski | Nov 1993 | A |
5279550 | Habib et al. | Jan 1994 | A |
5358492 | Feibus | Oct 1994 | A |
5370610 | Reynolds | Dec 1994 | A |
5383476 | Peimer | Jan 1995 | A |
5386835 | Elphick | Feb 1995 | A |
5449347 | Preen et al. | Sep 1995 | A |
5466229 | Elson | Nov 1995 | A |
5520652 | Peterson | May 1996 | A |
5527293 | Zamierowski | Jun 1996 | A |
5531855 | Heinecke et al. | Jul 1996 | A |
5599289 | Castellana | Feb 1997 | A |
5599333 | Atkinson | Feb 1997 | A |
5618556 | Johns et al. | Apr 1997 | A |
5636643 | Argenta et al. | Jun 1997 | A |
5645081 | Argenta et al. | Jul 1997 | A |
5678564 | Lawrence et al. | Oct 1997 | A |
5701917 | Khouri | Dec 1997 | A |
5704905 | Jensen | Jan 1998 | A |
5735833 | Olson | Apr 1998 | A |
5738656 | Wagner | Apr 1998 | A |
5753285 | Horan | May 1998 | A |
5795584 | Totakura et al. | Aug 1998 | A |
5816252 | Faries, Jr. | Oct 1998 | A |
5885237 | Kadash et al. | Mar 1999 | A |
5911222 | Lawrence et al. | Jun 1999 | A |
5979226 | Cavestri | Nov 1999 | A |
6070454 | Cavestri | Jun 2000 | A |
6070455 | Cavestri | Jun 2000 | A |
6071267 | Zamierowski | Jun 2000 | A |
D430674 | Dunshee et al. | Sep 2000 | S |
6117111 | Fleischmann | Sep 2000 | A |
6142982 | Hunt et al. | Nov 2000 | A |
6149614 | Dunshee et al. | Nov 2000 | A |
6345623 | Heaton | Feb 2002 | B1 |
6458109 | Henley et al. | Oct 2002 | B1 |
6500112 | Khouri | Dec 2002 | B1 |
6553998 | Heaton | Apr 2003 | B2 |
6626891 | Ohmstede | Sep 2003 | B2 |
6648862 | Watson | Nov 2003 | B2 |
6685681 | Lockwood et al. | Feb 2004 | B2 |
6685682 | Heinecke et al. | Feb 2004 | B1 |
6695823 | Lina | Feb 2004 | B1 |
6752794 | Lockwood et al. | Jun 2004 | B2 |
6755807 | Risk et al. | Jun 2004 | B2 |
6764462 | Risk, Jr. et al. | Jul 2004 | B2 |
6800074 | Henley et al. | Oct 2004 | B2 |
6855135 | Lockwood et al. | Feb 2005 | B2 |
6936037 | Bubb et al. | Aug 2005 | B2 |
6942687 | Heaton et al. | Sep 2005 | B1 |
6951553 | Bubb et al. | Oct 2005 | B2 |
6960190 | Stinson | Nov 2005 | B2 |
D515701 | Horhota et al. | Feb 2006 | S |
7004915 | Boynton et al. | Feb 2006 | B2 |
7022113 | Lockwood et al. | Apr 2006 | B2 |
7070584 | Johnson et al. | Jul 2006 | B2 |
7108683 | Zamierowski | Sep 2006 | B2 |
7128735 | Weston | Oct 2006 | B2 |
7195624 | Lockwood | Mar 2007 | B2 |
7198046 | Argenta et al. | Apr 2007 | B1 |
7216651 | Argenta et al. | May 2007 | B2 |
7279612 | Heaton | Oct 2007 | B1 |
7316672 | Hunt et al. | Jan 2008 | B1 |
7338482 | Lockwood et al. | Mar 2008 | B2 |
7381859 | Hunt et al. | Jun 2008 | B2 |
7438705 | Karpowicz et al. | Oct 2008 | B2 |
7485112 | Karpowicz et al. | Feb 2009 | B2 |
7503910 | Adahan | Mar 2009 | B2 |
7524315 | Blott et al. | Apr 2009 | B2 |
7531711 | Sigurjonsson et al. | May 2009 | B2 |
7534927 | Lockwood | May 2009 | B2 |
7553306 | Hunt et al. | Jun 2009 | B1 |
7569742 | Haggstrom et al. | Aug 2009 | B2 |
7608066 | Vogel | Oct 2009 | B2 |
7625362 | Boehringer et al. | Dec 2009 | B2 |
7645269 | Zamierowski | Jan 2010 | B2 |
7651484 | Heaton et al. | Jan 2010 | B2 |
7670323 | Hunt et al. | Mar 2010 | B2 |
7678102 | Heaton | Mar 2010 | B1 |
7686785 | Boehringer et al. | Mar 2010 | B2 |
7699830 | Martin | Apr 2010 | B2 |
7700819 | Ambrosio et al. | Apr 2010 | B2 |
7708724 | Weston | May 2010 | B2 |
7709694 | Batich | May 2010 | B2 |
7722582 | Lina et al. | May 2010 | B2 |
7753894 | Blott et al. | Jul 2010 | B2 |
7754936 | Heaton et al. | Jul 2010 | B2 |
7776028 | Miller et al. | Aug 2010 | B2 |
7794438 | Henley et al. | Sep 2010 | B2 |
7794450 | Blott et al. | Sep 2010 | B2 |
7858679 | Messersmith | Dec 2010 | B2 |
7862718 | Doyen et al. | Jan 2011 | B2 |
7880050 | Robinson et al. | Feb 2011 | B2 |
7883494 | Martin | Feb 2011 | B2 |
7909805 | Weston | Mar 2011 | B2 |
7922703 | Riesinger | Apr 2011 | B2 |
7943380 | Westman | May 2011 | B2 |
7951100 | Hunt et al. | May 2011 | B2 |
7951124 | Boehringer et al. | May 2011 | B2 |
7964766 | Blott et al. | Jun 2011 | B2 |
7981098 | Boehringer et al. | Jul 2011 | B2 |
7994383 | Zocher | Aug 2011 | B2 |
7999145 | Kairinos | Aug 2011 | B2 |
8002313 | Singh et al. | Aug 2011 | B2 |
8021347 | Vitaris et al. | Sep 2011 | B2 |
8057449 | Sanders | Nov 2011 | B2 |
8062272 | Weston | Nov 2011 | B2 |
8083712 | Biggie et al. | Dec 2011 | B2 |
8092441 | Sugito | Jan 2012 | B2 |
8105295 | Blott et al. | Jan 2012 | B2 |
8118794 | Weston et al. | Feb 2012 | B2 |
8133211 | Cavanaugh, II et al. | Mar 2012 | B2 |
8147468 | Barta et al. | Apr 2012 | B2 |
8148595 | Robinson et al. | Apr 2012 | B2 |
8152785 | Vitaris | Apr 2012 | B2 |
8157775 | Bobroff | Apr 2012 | B2 |
8158844 | McNeil | Apr 2012 | B2 |
8162907 | Heagle | Apr 2012 | B2 |
8168848 | Lockwood et al. | May 2012 | B2 |
8187237 | Seegert | May 2012 | B2 |
8188331 | Barta et al. | May 2012 | B2 |
8202261 | Kazala, Jr. et al. | Jun 2012 | B2 |
8211073 | Dove | Jul 2012 | B2 |
8235955 | Blott et al. | Aug 2012 | B2 |
8241261 | Randolph et al. | Aug 2012 | B2 |
8246606 | Stevenson et al. | Aug 2012 | B2 |
8257327 | Blott et al. | Sep 2012 | B2 |
8267908 | Coulthard | Sep 2012 | B2 |
8282611 | Weston | Oct 2012 | B2 |
8298200 | Vess | Oct 2012 | B2 |
8303552 | Weston | Nov 2012 | B2 |
8317774 | Adahan | Nov 2012 | B2 |
8348910 | Blott et al. | Jan 2013 | B2 |
8366692 | Weston | Feb 2013 | B2 |
8376972 | Fleischmann | Feb 2013 | B2 |
8382731 | Johannison | Feb 2013 | B2 |
8430867 | Robinson | Apr 2013 | B2 |
8449508 | Coulthard et al. | May 2013 | B2 |
8449509 | Weston | May 2013 | B2 |
8460255 | Joshi et al. | Jun 2013 | B2 |
8506554 | Adahan | Aug 2013 | B2 |
8545466 | Andresen et al. | Oct 2013 | B2 |
8641691 | Fink | Feb 2014 | B2 |
8734410 | Hall | May 2014 | B2 |
8771244 | Eckstein et al. | Jul 2014 | B2 |
8784392 | Vess | Jul 2014 | B2 |
8784393 | Weston et al. | Jul 2014 | B2 |
8795243 | Weston | Aug 2014 | B2 |
8801685 | Armstrong et al. | Aug 2014 | B2 |
8808274 | Hartwell | Aug 2014 | B2 |
8814842 | Coulthard et al. | Aug 2014 | B2 |
8843327 | Vernon-Harcourt et al. | Sep 2014 | B2 |
8915896 | Sanders | Dec 2014 | B2 |
9017302 | Vitaris et al. | Apr 2015 | B2 |
9033942 | Vess | May 2015 | B2 |
9044579 | Blott et al. | Jun 2015 | B2 |
9061095 | Adie et al. | Jun 2015 | B2 |
9199012 | Vitaris et al. | Dec 2015 | B2 |
9227000 | Fink et al. | Jan 2016 | B2 |
9302032 | Bannister et al. | Apr 2016 | B2 |
9474654 | Heagle et al. | Oct 2016 | B2 |
9801985 | Hall | Oct 2017 | B2 |
20020044891 | Miller | Apr 2002 | A1 |
20030040687 | Boynton | Feb 2003 | A1 |
20030069529 | Augustine et al. | Apr 2003 | A1 |
20030097100 | Watson | May 2003 | A1 |
20030212357 | Pace | Nov 2003 | A1 |
20040006319 | Lina | Jan 2004 | A1 |
20040030304 | Hunt | Feb 2004 | A1 |
20040200480 | Faries, Jr. | Oct 2004 | A1 |
20040200483 | Faries, Jr. | Oct 2004 | A1 |
20040208780 | Faries, Jr. | Oct 2004 | A1 |
20040258562 | Mills | Dec 2004 | A1 |
20050004534 | Lockwood | Jan 2005 | A1 |
20050085795 | Lockwood | Apr 2005 | A1 |
20050101940 | Radl et al. | May 2005 | A1 |
20050112772 | Farone | May 2005 | A1 |
20050131327 | Lockwood et al. | Jun 2005 | A1 |
20060100586 | Karpowicz | May 2006 | A1 |
20060155260 | Blott | Jul 2006 | A1 |
20060194324 | Faries, Jr. | Aug 2006 | A1 |
20070005028 | Risk et al. | Jan 2007 | A1 |
20070016152 | Karpowicz | Jan 2007 | A1 |
20070027423 | Scheinberg et al. | Feb 2007 | A1 |
20070032778 | Heaton et al. | Feb 2007 | A1 |
20070038172 | Zamierowski | Feb 2007 | A1 |
20070078366 | Haggstrom | Apr 2007 | A1 |
20070078444 | Larsson | Apr 2007 | A1 |
20070089753 | Faries, Jr. | Apr 2007 | A1 |
20070156104 | Lockwood et al. | Jul 2007 | A1 |
20070167926 | Blott | Jul 2007 | A1 |
20070179460 | Adahan | Aug 2007 | A1 |
20070219532 | Karpowicz | Sep 2007 | A1 |
20070225663 | Watt et al. | Sep 2007 | A1 |
20070260226 | Jaeb et al. | Nov 2007 | A1 |
20070265586 | Joshi | Nov 2007 | A1 |
20070282310 | Bengtson et al. | Dec 2007 | A1 |
20080033325 | Van der Hulst et al. | Feb 2008 | A1 |
20080071214 | Locke | Mar 2008 | A1 |
20080071216 | Locke et al. | Mar 2008 | A1 |
20080148817 | Miller | Jun 2008 | A1 |
20080200906 | Sanders et al. | Aug 2008 | A1 |
20080234641 | Locke | Sep 2008 | A1 |
20090030383 | Larsen et al. | Jan 2009 | A1 |
20090054855 | Blott et al. | Feb 2009 | A1 |
20090131892 | Karpowicz et al. | May 2009 | A1 |
20090157016 | Adahan | Jun 2009 | A1 |
20090192467 | Hansen et al. | Jul 2009 | A1 |
20090198201 | Adahan | Aug 2009 | A1 |
20090221977 | Blott et al. | Sep 2009 | A1 |
20090227969 | Jaeb | Sep 2009 | A1 |
20090234309 | Vitaris | Sep 2009 | A1 |
20090238811 | McDaniel | Sep 2009 | A1 |
20090254053 | Svensby et al. | Oct 2009 | A1 |
20090254066 | Heaton | Oct 2009 | A1 |
20090293887 | Wilkes et al. | Dec 2009 | A1 |
20090299249 | Wilkes et al. | Dec 2009 | A1 |
20090299255 | Kazala, Jr. et al. | Dec 2009 | A1 |
20090299257 | Long et al. | Dec 2009 | A1 |
20090299308 | Kazala et al. | Dec 2009 | A1 |
20090299340 | Kazala et al. | Dec 2009 | A1 |
20090301382 | Patel | Dec 2009 | A1 |
20090312723 | Blott | Dec 2009 | A1 |
20100016767 | Jones et al. | Jan 2010 | A1 |
20100022972 | Lina et al. | Jan 2010 | A1 |
20100030167 | Thirstrup | Feb 2010 | A1 |
20100069850 | Fabo | Mar 2010 | A1 |
20100069863 | Olson | Mar 2010 | A1 |
20100069886 | Wilkes | Mar 2010 | A1 |
20100094234 | Ramella et al. | Apr 2010 | A1 |
20100106114 | Weston | Apr 2010 | A1 |
20100106117 | Lockwood et al. | Apr 2010 | A1 |
20100106188 | Heaton et al. | Apr 2010 | A1 |
20100125258 | Coulthard et al. | May 2010 | A1 |
20100125259 | Olson | May 2010 | A1 |
20100160901 | Hu et al. | Jun 2010 | A1 |
20100168691 | Long et al. | Jul 2010 | A1 |
20100211030 | Turner et al. | Aug 2010 | A1 |
20100233146 | McDaniel | Sep 2010 | A1 |
20100234818 | Aali | Sep 2010 | A1 |
20100249733 | Blott et al. | Sep 2010 | A9 |
20100262095 | Hall | Oct 2010 | A1 |
20100324516 | Braga et al. | Dec 2010 | A1 |
20110015619 | Svedman | Jan 2011 | A1 |
20110028920 | Johannison | Feb 2011 | A1 |
20110034888 | Aali | Feb 2011 | A1 |
20110112492 | Bharti | May 2011 | A1 |
20110118683 | Weston | May 2011 | A1 |
20110130712 | Topaz | Jun 2011 | A1 |
20110245682 | Robinson | Oct 2011 | A1 |
20110250626 | Williams | Oct 2011 | A1 |
20110251569 | Turner et al. | Oct 2011 | A1 |
20110259086 | Harris | Oct 2011 | A1 |
20110275159 | Landgrebe | Nov 2011 | A1 |
20120095380 | Gergley et al. | Apr 2012 | A1 |
20120109085 | McNeil | May 2012 | A1 |
20120130332 | Cotton et al. | May 2012 | A1 |
20120143155 | Edvardsen | Jun 2012 | A1 |
20120143156 | Bannister | Jun 2012 | A1 |
20120302976 | Locke et al. | Nov 2012 | A1 |
20130066285 | Locke | Mar 2013 | A1 |
20130150814 | Buan | Jun 2013 | A1 |
20130172835 | Braga et al. | Jul 2013 | A1 |
20130226152 | Zolli | Aug 2013 | A1 |
20140088534 | Kanakkanatt | Mar 2014 | A1 |
20140154808 | Patel | Jun 2014 | A1 |
20140330225 | Hall | Nov 2014 | A1 |
20140350494 | Hartwell | Nov 2014 | A1 |
20150045752 | Grillitsch et al. | Feb 2015 | A1 |
20150073358 | Jaeb et al. | Mar 2015 | A1 |
20150141941 | Allen | May 2015 | A1 |
20160158056 | Davis | Jun 2016 | A1 |
Number | Date | Country |
---|---|---|
674837 | Jan 1997 | AU |
3 935 818 | May 1991 | DE |
198 44 355 | Apr 2000 | DE |
0 392 640 | Jun 1995 | EP |
0 441 418 | Jul 1995 | EP |
0 465 601 | Jan 1997 | EP |
0 751 757 | Jan 1997 | EP |
0 853 950 | Jul 1998 | EP |
0 777 504 | Oct 1998 | EP |
1 018 967 | Jul 2000 | EP |
0 688 189 | Sep 2000 | EP |
0 690 706 | Nov 2000 | EP |
0 865 304 | Jul 2001 | EP |
0 921 775 | Dec 2001 | EP |
1 169 071 | Jan 2002 | EP |
0 708 620 | May 2003 | EP |
1 088 569 | Aug 2003 | EP |
0 993 317 | Sep 2003 | EP |
1 440 667 | Jul 2004 | EP |
1 578 477 | Jul 2004 | EP |
1 018 967 | Aug 2004 | EP |
1 448 261 | Aug 2004 | EP |
1 100 574 | Feb 2005 | EP |
1 513 478 | Mar 2005 | EP |
0 688 189 | Jun 2005 | EP |
1 637 088 | Mar 2006 | EP |
1 284 777 | Apr 2006 | EP |
0 982 015 | Aug 2006 | EP |
0 620 720 | Nov 2006 | EP |
1 171 065 | Mar 2007 | EP |
1 772 160 | Apr 2007 | EP |
1 227 853 | Jan 2008 | EP |
1 476 217 | Mar 2008 | EP |
1 233 808 | Jul 2008 | EP |
1 977 776 | Oct 2008 | EP |
2 127 690 | Dec 2009 | EP |
1 905 465 | Jan 2010 | EP |
2 172 164 | Apr 2010 | EP |
1 703 922 | May 2011 | EP |
2 319 550 | May 2011 | EP |
1 487 389 | Oct 2011 | EP |
2 529 766 | Dec 2012 | EP |
2 545 946 | Mar 2013 | EP |
2 659 915 | Nov 2013 | EP |
2 628 500 | May 2014 | EP |
1 339 366 | Jun 2014 | EP |
2 051 675 | Jun 2014 | EP |
1 163 907 | Oct 1958 | FR |
2307180 | May 1997 | GB |
2329127 | Mar 1999 | GB |
2336546 | Oct 1999 | GB |
2344531 | Jul 2000 | GB |
S61-80018 | May 1986 | JP |
2005-334188 | Dec 2005 | JP |
WO 1997018007 | May 1997 | WO |
WO 199901173 | Jan 1999 | WO |
WO 200021586 | Apr 2000 | WO |
WO 2003030966 | Apr 2003 | WO |
WO 2003045492 | Jun 2003 | WO |
WO 2003057070 | Jul 2003 | WO |
WO 2003086232 | Oct 2003 | WO |
WO 2003092620 | Nov 2003 | WO |
WO 2003101508 | Dec 2003 | WO |
WO 2004037334 | May 2004 | WO |
WO 2004060148 | Jul 2004 | WO |
WO 200504670 | Jan 2005 | WO |
WO 2005016179 | Feb 2005 | WO |
WO 2005061025 | Jul 2005 | WO |
WO 2005105174 | Nov 2005 | WO |
WO 2005105180 | Nov 2005 | WO |
WO 2006052338 | May 2006 | WO |
WO 2006052745 | May 2006 | WO |
WO 2007006306 | Jan 2007 | WO |
WO 2007013049 | Feb 2007 | WO |
WO 2007013064 | Feb 2007 | WO |
WO 2007016590 | Feb 2007 | WO |
WO 2007019038 | Feb 2007 | WO |
WO 2007041642 | Apr 2007 | WO |
WO 2007067685 | Jun 2007 | WO |
WO 2007085396 | Aug 2007 | WO |
WO 2007087810 | Aug 2007 | WO |
WO 2007092397 | Aug 2007 | WO |
WO 2007095180 | Aug 2007 | WO |
WO 2007106590 | Sep 2007 | WO |
WO 2007106591 | Sep 2007 | WO |
WO 2008008032 | Jan 2008 | WO |
WO 2008010094 | Jan 2008 | WO |
WO 2008012278 | Jan 2008 | WO |
WO 2008027449 | Mar 2008 | WO |
WO 2008030872 | Mar 2008 | WO |
WO 2008036360 | Mar 2008 | WO |
WO 2008039314 | Apr 2008 | WO |
WO 2008043067 | Apr 2008 | WO |
WO 2008048481 | Apr 2008 | WO |
WO 2008100437 | Aug 2008 | WO |
WO 2008100440 | Aug 2008 | WO |
WO 2008100446 | Aug 2008 | WO |
WO 2008131895 | Nov 2008 | WO |
WO 2008135997 | Nov 2008 | WO |
WO 2008141470 | Nov 2008 | WO |
WO 2009002260 | Dec 2008 | WO |
WO 2009019419 | Feb 2009 | WO |
WO 2009019495 | Feb 2009 | WO |
WO 2009066104 | May 2009 | WO |
WO 2009068665 | Jun 2009 | WO |
WO 2009071933 | Jun 2009 | WO |
WO 2009086580 | Jul 2009 | WO |
WO 2009088925 | Jul 2009 | WO |
WO 2009089390 | Jul 2009 | WO |
WO 2009111655 | Sep 2009 | WO |
WO 2009126103 | Oct 2009 | WO |
WO 2009137194 | Nov 2009 | WO |
WO 2009140376 | Nov 2009 | WO |
WO 2009141820 | Nov 2009 | WO |
WO 2009145894 | Dec 2009 | WO |
WO 2009158125 | Dec 2009 | WO |
WO 2009158126 | Dec 2009 | WO |
WO 2009158127 | Dec 2009 | WO |
WO 2009158129 | Dec 2009 | WO |
WO 2010014177 | Feb 2010 | WO |
WO 2010033271 | Mar 2010 | WO |
WO 2010033272 | Mar 2010 | WO |
WO 2010033769 | Mar 2010 | WO |
WO 2010042240 | Apr 2010 | WO |
WO 2010051073 | May 2010 | WO |
WO 2010059712 | May 2010 | WO |
WO 2010059730 | May 2010 | WO |
WO 2010078166 | Jul 2010 | WO |
WO 2010120470 | Oct 2010 | WO |
WO 2010147533 | Dec 2010 | WO |
WO 2011049562 | Apr 2011 | WO |
WO 2011100851 | Aug 2011 | WO |
WO 2011115908 | Sep 2011 | WO |
WO 2012142002 | Oct 2012 | WO |
WO 2012166428 | Dec 2012 | WO |
WO 2012174672 | Dec 2012 | WO |
WO 2013013938 | Jan 2013 | WO |
WO 2013016239 | Jan 2013 | WO |
WO 2013019438 | Feb 2013 | WO |
WO 2013043972 | Mar 2013 | WO |
WO 2013123005 | Aug 2013 | WO |
WO 2014066057 | May 2014 | WO |
WO 2014043238 | Sep 2014 | WO |
WO 2014158526 | Oct 2014 | WO |
WO 2015018720 | Feb 2015 | WO |
Entry |
---|
US 7,186,244 B1, 03/2007, Hunt et al. (withdrawn) |
International Preliminary Report on Patentability, re PCT Application No. PCT/GB2008/051118, dated Jun. 8, 2010. |
Boehringer Wound Systems, LLC, Engenex™ Instructions for Use, Aug. 2007, pp. 1-33. |
Edlich, R. F. et al., “Evaluation of a New, Improved Surgical Drainage System”, The American Journal of Surgery, vol. 149, Issue 2, Feb. 1985, pp. 295-298. |
Info V.A.C. User Manual—KCI—Dec. 2006, in 76 pages. |
International Search Report, re PCT Application No. PCT/GB2008/050507, dated Oct. 15, 2008. |
International Search Report, re PCT Application No. PCT/GB2008/051118, dated Jun. 19, 2009. |
Smith, S.R.G., “Surgical Drainage,” British Journal of Hospital Medicine, Jun. 1985, pp. 308-315. |
Van Way III, MD, Charles W., “Prevention of sunction-induced gastric mucosal damage in dogs,” Critical Care Medicine, 1987, pp. 774-777, vol. 15, No. 8. |
Worth, M.H., M.D. and H.W. Anderson, M.D., “The Effectiveness of Bacterial Filtration in Vented Wound Drains,” Journal of Surgical Research, 1979, pp. 405-407. |
Annex to the Communication, re the Opposition of European Patent No. EP 2 231 218, dated Apr. 17, 2019, in 10 pages. |
Brief Communication—Letter from the Proprietor of the Patent, re the Opposition of European Patent No. EP 2 231 218, dated Dec. 18, 2018, in 24 pages. |
Reply of the Patent Proprietor to the Notice(s) of Opposition, re the Opposition of European Patent No. EP 2 231 218, dated Nov. 28, 2018, in 26 pages. |
Communication of a Notice of Opposition including Statement of Facts and Evidence, re European Patent No. EP 2 231 218, dated Jul. 2, 2018, in 17 pages. |
Notice of Opposition—Statement of Facts and Evidence, re European Patent No. EP 2 231 218, dated Jun. 21, 2018, in 16 pages. |
Number | Date | Country | |
---|---|---|---|
20180126051 A1 | May 2018 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14267721 | May 2014 | US |
Child | 15797899 | US | |
Parent | 12746458 | US | |
Child | 14267721 | US |